Multiple Sclerosis Trial, Recruiting (ISRCTN31489759)

Multiple Sclerosis Trial, Recruiting ISRCTN31489759 Sponsor: Roche (France) Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — ISRCTN31489759 — Data sourced from the ISRCTN registry. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go) based on recognised diagnostic guidelines from 2017 or 2024
People aged 18 years or older
People for whom a healthcare professional has planned to start treatment with a specific medication called ocrelizumab (given by injection under the skin), either after switching from certain previous MS treatments or with no prior MS treatment
People who are physically and mentally able to complete questionnaires and tests as part of the study
People who own a smartphone, tablet, or computer with an internet connection
People who do not object to taking part and having their data used for the study

Who may not be able to join:

People for whom the planned use of the medication does not follow standard medical practice or the official approved guidelines for that medication
People who are under legal guardianship or court-ordered protection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from the ISRCTN registry. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 10 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: ISRCTN31489759

Sponsor: Roche (France)

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

More information: https://www.isrctn.com/ISRCTN31489759

Eligibility summary (AI generated)

Written by an AI model from the ISRCTN registry eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go) based on recognised diagnostic guidelines from 2017 or 2024
People aged 18 years or older
People for whom a healthcare professional has planned to start treatment with a specific medication called ocrelizumab (given by injection under the skin), either after switching from certain previous MS treatments or with no prior MS treatment
People who are physically and mentally able to complete questionnaires and tests as part of the study
People who own a smartphone, tablet, or computer with an internet connection
People who do not object to taking part and having their data used for the study

Who may not be able to join:

People for whom the planned use of the medication does not follow standard medical practice or the official approved guidelines for that medication
People who are under legal guardianship or court-ordered protection

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from the ISRCTN registry via Voxsanity (data last synced 10 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Roche (France)

Registry

ISRCTN registry

Start date

9 February 2026

Est. completion

28 February 2029

Where this trial is recruiting

🇫🇷 France

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from the ISRCTN registry: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ISRCTN ↗

Source: ISRCTN registry (isrctn.com), data processed 10 July 2026. ISRCTN metadata is CC0; contribution content is CC BY 4.0.